Eshmun Biotech Profile
Key Indicators
- Authorised Capital ₹ 2.00 M
as on 11-12-2024
- Paid Up Capital ₹ 2.00 M
as on 11-12-2024
- Company Age 9 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 4.70 M
as on 11-12-2024
- Revenue 14.31%
(FY 2023)
- Profit -16.48%
(FY 2023)
- Ebitda 44.50%
(FY 2023)
- Net Worth 19.56%
(FY 2023)
- Total Assets 31.66%
(FY 2023)
About Eshmun Biotech
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.00 M and a paid-up capital of Rs 2.00 M.
The company currently has active open charges totaling ₹4.70 M.
Parshotam Dass and Umesh Mehta serve as directors at the Company.
- CIN/LLPIN
U24232PB2015PTC039516
- Company No.
039516
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 Jun 2015
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- Location
Bathinda, Punjab, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Eshmun Biotech Private Limited offer?
Eshmun Biotech Private Limited offers a wide range of products and services, including Common Disease Medicines, Pharmaceutical Tablets, Eye Care Medicines, Pain Relief Drugs & Pharmaceuticals, Muscle Relaxant, Anti Infective Drugs & Medicines, Antibiotic Tablets, Capsule & Syrup, Digestive System Drugs & Medicines, Dicyclomine Hydrochloride Medicine, Anti Inflammatory Drugs.
Who are the key members and board of directors at Eshmun Biotech?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Parshotam Dass  | Director | 05-Jun-2015 | Current |
| Umesh Mehta | Director | 05-Jun-2015 | Current |
Financial Performance of Eshmun Biotech.
Eshmun Biotech Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 14.31% increase. The company also saw a substantial fall in profitability, with a 16.48% decrease in profit. The company's net worth Soared by an impressive increase of 19.56%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Eshmun Biotech?
Unlock access to Eshmun Biotech's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Dena Bank Creation Date: 26 Feb 2016 | ₹4.70 M | Open |
How Many Employees Work at Eshmun Biotech?
Unlock and access historical data on people associated with Eshmun Biotech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Eshmun Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Eshmun Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
